Johnson & Johnson Profit Beats Estimates on Drug Sales
Published: Oct 15, 2013
Johnson & Johnson (JNJ), the world’s biggest maker of health-care products, reported third-quarter profit that beat analysts’ estimates as newer drugs continue to propel the company to faster growth than competitors. J&J raised its full-year forecast. Earnings excluding one-time items of $1.36 a share beat the $1.32 average of 17 analysts’ estimates compiled by Bloomberg.
Help employers find you! Check out all the jobs and post your resume.